↓ Skip to main content

Glucagon and heart in type 2 diabetes: new perspectives

Overview of attention for article published in Cardiovascular Diabetology, August 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
7 tweeters
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
50 Dimensions

Readers on

mendeley
93 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Glucagon and heart in type 2 diabetes: new perspectives
Published in
Cardiovascular Diabetology, August 2016
DOI 10.1186/s12933-016-0440-3
Pubmed ID
Authors

Antonio Ceriello, Stefano Genovese, Edoardo Mannucci, Edoardo Gronda

Abstract

Increased levels of glucagon in type 2 diabetes are well known and, until now, have been considered deleterious. However, glucagon has an important role in the maintenance of both heart and kidney function. Moreover, in the past, glucagon has been therapeutically used for heart failure treatment. The new antidiabetic drugs, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors, are able to decrease and to increase glucagon levels, respectively, while contrasting data have been reported regarding the glucagon like peptide 1 receptors agonists. The cardiovascular outcome trials, requested by the FDA, raised some concerns about the possibility that the dipeptidyl peptidase-4 inhibitors can precipitate the heart failure, while, at least for empagliflozin, a positive effect has been shown in decreasing both cardiovascular death and heart failure. The recent LEADER Trial, showed a significant reduction of cardiovascular death with liraglutide, but a neutral effect on heart failure. A possible explanation of the results with the DPPIV inhibitors and empagliflozin might be related to their divergent effect on glucagon levels. Due to unclear effects of glucagon like peptide 1 receptor agonists on glucagon, the possible role of this hormone in the Leader trial remains unclear.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 93 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 19%
Other 13 14%
Student > Ph. D. Student 11 12%
Student > Master 10 11%
Student > Bachelor 8 9%
Other 19 20%
Unknown 14 15%
Readers by discipline Count As %
Medicine and Dentistry 40 43%
Biochemistry, Genetics and Molecular Biology 9 10%
Pharmacology, Toxicology and Pharmaceutical Science 7 8%
Agricultural and Biological Sciences 5 5%
Unspecified 3 3%
Other 3 3%
Unknown 26 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2021.
All research outputs
#4,077,212
of 22,884,315 outputs
Outputs from Cardiovascular Diabetology
#263
of 1,386 outputs
Outputs of similar age
#69,357
of 338,387 outputs
Outputs of similar age from Cardiovascular Diabetology
#7
of 34 outputs
Altmetric has tracked 22,884,315 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,386 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,387 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.